Tenon Medical, Inc. reported preliminary unaudited revenue ranges showing strong growth for 2025. Fourth quarter 2025 revenue is expected between $1.45 million and $1.48 million, which the company says is about 90% higher year over year compared with the fourth quarter of 2024.
For full year 2025, Tenon expects unaudited revenue between $3.91 million and $3.94 million, representing roughly 20% year-over-year growth versus 2024. The company plans to release full financial results after market close on March 19, 2026 and will host a conference call that day at 4:30 p.m. Eastern Time to discuss the results in more detail.
Tenon Medical, Inc. filed an 8-K dated September 23, 2025 that lists its publicly traded securities and records signatures and share-count figures for several named officers and directors. The document references Common Stock (par value $0.001) trading under the symbol TNON and Warrants trading under TNONW on The Nasdaq Stock Market. Individual entries show numeric holdings for Steven Foster, Richard Ginn, Stephen Hochschuler, MD, Ivan Howard, Kristine Jacques, and Robert Weigle, and the filing is executed by Steven M. Foster in his capacity as Chief Executive Officer and President.
Tenon Medical, Inc. has rescheduled its previously adjourned Annual Meeting to be held virtually on September 18, 2025, at 10:30 a.m. Pacific Time. The meeting had been adjourned on July 23, 2025 and August 20, 2025.
Only shareholders of record at the close of business on August 22, 2025 are entitled to notice and to vote. Stockholders must use a Virtual Control Number to participate and vote electronically, with additional steps required for those holding shares in “street name.” The company urges shareholders to vote before September 16, 2025 to ensure their votes are received and counted.